Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock price shot up 2.6% during trading on Thursday . The stock traded as high as $853.66 and last traded at $850.69. 760,427 shares traded hands during trading, a decline of 78% from the average session volume of 3,422,504 shares. The stock had previously closed at $829.42.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the company. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Citigroup decreased their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Guggenheim dropped their price target on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Finally, Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research report on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,017.00.
Check Out Our Latest Analysis on Eli Lilly and Company
Eli Lilly and Company Stock Up 2.9 %
The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock's fifty day simple moving average is $827.69 and its 200-day simple moving average is $817.91. The stock has a market cap of $839.07 billion, a P/E ratio of 75.57, a PEG ratio of 1.40 and a beta of 0.51.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.
Insider Buying and Selling
In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.13% of the company's stock.
Hedge Funds Weigh In On Eli Lilly and Company
A number of institutional investors and hedge funds have recently bought and sold shares of LLY. West Bancorporation Inc. lifted its stake in shares of Eli Lilly and Company by 53.1% in the 1st quarter. West Bancorporation Inc. now owns 565 shares of the company's stock worth $467,000 after acquiring an additional 196 shares during the period. Kampmann Melissa S. raised its holdings in Eli Lilly and Company by 0.5% during the first quarter. Kampmann Melissa S. now owns 8,511 shares of the company's stock worth $7,029,000 after purchasing an additional 40 shares in the last quarter. Mather Group LLC. lifted its position in Eli Lilly and Company by 13.3% in the first quarter. Mather Group LLC. now owns 8,374 shares of the company's stock worth $6,916,000 after purchasing an additional 982 shares during the period. Alta Advisers Ltd boosted its stake in Eli Lilly and Company by 57.3% during the 1st quarter. Alta Advisers Ltd now owns 4,119 shares of the company's stock valued at $3,402,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Hixon Zuercher LLC raised its stake in shares of Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after buying an additional 12 shares in the last quarter. Institutional investors own 82.53% of the company's stock.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
